Yes, you can take prednisone with methotrexate—this combination is well-established and often beneficial across multiple conditions.
Evidence Supporting Combined Use
The combination of prednisone and methotrexate is not only safe but frequently recommended in clinical practice. Multiple high-quality guidelines explicitly support this combination therapy across various rheumatic and inflammatory conditions.
Rheumatoid Arthritis
In rheumatoid arthritis, the evidence strongly supports combining these medications:
- Combination therapy including prednisone or anti-TNF agents with methotrexate has well-established superiority over methotrexate monotherapy 1
- The 2021 ACR guidelines acknowledge that while they conditionally recommend against routine long-term glucocorticoid use, short-term glucocorticoids are frequently necessary and appropriate when starting DMARDs like methotrexate 2
- The CAMERA-II trial demonstrated that adding prednisone 10 mg daily to methotrexate-based tight control strategy in early RA significantly improved outcomes, reduced erosive joint damage, achieved more sustained remissions, and actually had similar or fewer adverse events compared to methotrexate alone 3
Importantly, prednisone may actually reduce methotrexate side effects. A 2023 study found that adding 10 mg prednisone daily to methotrexate significantly decreased common methotrexate side effects (OR 0.54), specifically reducing nausea (OR 0.46) and elevated liver enzymes (OR 0.29) 4. This suggests a protective effect beyond just disease control.
Other Inflammatory Conditions
The combination is recommended or supported across multiple conditions:
- Giant cell arteritis and polymyalgia rheumatica: Methotrexate is specifically recommended as a steroid-sparing agent in patients on high-dose prednisone, allowing for lower cumulative steroid doses and fewer relapses 1
- Systemic lupus erythematosus: Methotrexate with prednisone showed significantly more prednisone reduction and fewer disease flares 1
- Juvenile dermatomyositis: Concomitant methotrexate therapy allowed earlier prednisone discontinuation and lower cumulative doses 1
- Idiopathic inflammatory myopathies: Standard treatment protocols initiate prednisone 0.5-1 mg/kg daily concurrent with methotrexate as a steroid-sparing agent 5
- Crohn's disease: While guidelines focus on biologics, methotrexate is used with corticosteroids for induction in appropriate patients 6, 7
ANCA-Associated Vasculitis
In ANCA-associated vasculitis, methotrexate 20-25 mg/week combined with glucocorticoids is recommended as a less toxic alternative to cyclophosphamide for non-organ threatening disease 8
Practical Considerations
Monitoring Requirements
When using this combination:
- Routine monitoring of complete blood counts and liver function tests every 3-6 months is recommended for methotrexate 9
- Folic acid supplementation (5 mg weekly or 1 mg daily) should accompany methotrexate to reduce gastrointestinal and hepatic adverse effects 6, 9, 5, 7
- Osteoporosis prophylaxis should be implemented for patients on glucocorticoids 8
Common Pitfalls to Avoid
- Don't avoid this combination due to unfounded toxicity concerns—the evidence shows it's often safer and more effective than alternatives
- Don't use prednisone long-term without a steroid-sparing agent like methotrexate—this defeats the purpose of combination therapy
- Don't forget contraception counseling for women of childbearing age, as methotrexate is teratogenic and requires discontinuation at least 3 months before planned pregnancy 9, 1, 10
- Don't use preserved methotrexate formulations for intrathecal or high-dose therapy 10
Dosing Approach
Typical regimens combine:
- Methotrexate: 15-25 mg weekly (start lower and escalate) with folic acid supplementation
- Prednisone: Variable depending on condition—from 10 mg daily in RA to 1 mg/kg daily in severe inflammatory myopathies, with planned taper
The combination allows for more rapid disease control while the methotrexate takes effect (typically 3-6 months to full efficacy), then facilitates prednisone tapering to minimize long-term glucocorticoid toxicity.